Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
- Written by PR Newswire Asia - Asian Spectator
HIGHLIGHTS
- Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled and treated 3 participants who received therapy with 67Cu-SAR-bisPSMA at the highest dose level of 12GBq.
- No dose limiting toxicities (DLTs) have been reported to date. Only one...